JohnP.CookeMDPhD
Cardiology • Houston, TXVascular Medicine
Chair, Department of Cardiovascular Sciences Director, Center for Cardiovascular Regeneration The Methodist Hospital Research Institute
Dr. Cooke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6550 Fannin Street
Suite 1401
Houston, TX 77030Phone+1 713-441-5200Fax+1 713-793-7428
Summary
- Dr. John Cooke is Professor and Chair of the Department of Cardiovascular Sciences; Director, Center for Cardiovascular Regeneration; Medical Director, RNA Therapeutics Program; at Houston Methodist Research Institute; Weill Cornell Medical College; Adjunct Professor, Texas A&M School of Medicine.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 1983 - 1987- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1980 - 1982
Wayne State University School of MedicineClass of 1980
Certifications & Licensure
CA State Medical License 1990 - Present
TX State Medical License 2015 - 2026
MN State Medical License 1981 - 1988
IA State Medical License 1983 - 1986- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Understanding the Genetic Basis of Atherosclerosis and Peripheral Arterial Disease Start of enrollment: 2004 Apr 01
Publications & Presentations
PubMed
- Application of validated size-exclusion chromatography method for physicochemical characterization of topical gel formulation of deferoxamine conjugated with PEGylated...Adnan A Khan, Eman M Mohamed, Mohammad Kashif Iqubal, James M Tour, Emily A McHugh
International Journal of Pharmaceutics. 2024-12-05 - EphrinB2-mediated CDK5/ISL1 pathway enhances cardiac lymphangiogenesis and alleviates ischemic injury by resolving post-MI inflammation.Yingnan Bai, Liming Chen, Fanghao Guo, Jinghong Zhang, Jinlin Hu
Signal Transduction and Targeted Therapy. 2024-11-18 - 1 citationsA Potential Role for MAGI-1 in the Bi-Directional Relationship Between Major Depressive Disorder and Cardiovascular Disease.Priyanka Banerjee, Khanh Chau, Sivareddy Kotla, Eleanor L Davis, Estefani Berrios Turcios
Current Atherosclerosis Reports. 2024-09-01
Journal Articles
- Original Investigation Editorial Comment Novel Markers for Adverse Events in Atrial Fibrillation∗John Cooke, MD, ScienceDirect
Press Mentions
Vaccination Tied to Shorter COVID Illness, Less Viral SheddingOctober 18th, 2022- Houston Hospitals, Pharmacies to Soon Offer New COVID-19 Shots Targeting Omicron, BA.5 VariantsAugust 31st, 2022
- JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. To Scientific Advisory BoardJune 15th, 2021
- Join now to see all
Grant Support
- Cell Characterization And Imaging For Regenerative Therapies In Ischemic DiseasesNational Heart, Lung, And Blood Institute2012
- Mechanisms In Innovation In Vascular DiseaseNational Heart, Lung, And Blood Institute2011
- The Role Of The Nicotinic Cholinergic Pathway In Retinopathy Of PrematurityNational Eye Institute2011
- Basic And Translational Research Ipsc-Based Hematologic And Vascular TherapiesNational Heart, Lung, And Blood Institute2009–2011
- Stanford Career Development In Vascular MedicineNational Heart, Lung, And Blood Institute2007–2011
- Nce-Based Strategy For Nuclear Reprogramming And Regenerative MedicineNational Heart, Lung, And Blood Institute2009–2010
- Core--Clinical Research Skills DevelopmentNational Heart, Lung, And Blood Institute2006–2010
- Translational Research And Education In Cell Therapies For Vascular RegenerationNational Heart, Lung, And Blood Institute2009
- Signal-Transduction Of Endothelial Nachr In AngiogenesisNational Cancer Institute2005–2008
- ADMA: An Endogenous Inhibitor Of ESC Differentiation And EC RegenerationNational Heart, Lung, And Blood Institute2007
- Therapeutic Manipulation Of The NOS Pathway In Peripheral Arterial DiseaseNational Center For Research Resources2005–2007
- Stanford Vascular Biology And Medicine Training GrantNational Heart, Lung, And Blood Institute2003–2007
- Genetic Determinants Of PADNational Heart, Lung, And Blood Institute2003–2007
- ADMA: An Endogenous Inhibitor ESC Differentiation And ECNational Heart, Lung, And Blood Institute2006
- Effect Of ADMA And L-ArginineNational Center For Research Resources2006
- Heart Transplant Patients - Role Of Dysregulation Of The Nitric Oxide SynthaseNational Center For Research Resources2005
- Development Of Insulin Resistance In Patients With Peripheral Arterial DiseaseNational Center For Research Resources2005
- Peripheral Endothelial Vasomotor Function In TransplantsNational Center For Research Resources2004
- Manipulation Of The NOS Pathway In Arterial Disease-Dose-Ranging STUDY.National Center For Research Resources2004
- Double-Blind Placebo-Controlled Study Of Oral L-ArginineNational Center For Research Resources2004
- Phase 2: NOS Pathway In Arterial DiseaseNational Heart, Lung, And Blood Institute2003–2004
- Manipulation Of The NOS Pathway In Arterial DiseaseNational Heart, Lung, And Blood Institute2000–2004
- CMV And Dysregulation Of The NOS PathwayNational Institute Of Allergy And Infectious Diseases2001–2002
- Stanford Vascular Biology &Medicine Training GrantNational Heart, Lung, And Blood Institute1997–2001
- Vascular Disease Academic AwardNational Heart, Lung, And Blood Institute1991–1995
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
